SSB
REGN icon

Sandy Spring Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Sandy Spring Bank’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$31.7K Sell
50
-13
-21% -$8.94K ﹤0.01% 657
2024
Q4 		$44.5K Hold
63
– – ﹤0.01% 604
2024
Q3 		$65.7K Sell
63
-3
-5% -$3.34K ﹤0.01% 536
2024
Q2 		$68.8K Sell
66
-31
-32% -$30.1K ﹤0.01% 528
2024
Q1 		$92.9K Buy
97
+33
+52% +$31.4K ﹤0.01% 476
2023
Q4 		$55.8K Sell
64
-176
-73% -$145K ﹤0.01% 544
2023
Q3 		$197K Hold
240
– – 0.01% 346
2023
Q2 		$172K Buy
240
+1
+0.4% +$771 0.01% 366
2023
Q1 		$196K Hold
239
– – 0.01% 339
2022
Q4 		$172K Buy
239
+173
+262% +$128K 0.01% 356
2022
Q3 		$45K Buy
66
+2
+3% +$1.26K ﹤0.01% 532
2022
Q2 		$37K Buy
64
+2
+3% +$1.3K ﹤0.01% 573
2022
Q1 		$43K Hold
62
– – ﹤0.01% 572
2021
Q4 		$39K Hold
62
– – ﹤0.01% 625
2021
Q3 		$37K Hold
62
– – ﹤0.01% 628
2021
Q2 		$34K Buy
62
+50
+417% +$25.3K ﹤0.01% 660
2021
Q1 		$5K Sell
12
-4
-25% -$1.95K ﹤0.01% 877
2020
Q4 		$8K Hold
16
– – ﹤0.01% 781
2020
Q3 		$8K Hold
16
– – ﹤0.01% 705
2020
Q2 		$9K Buy
16
+4
+33% +$2.27K ﹤0.01% 714
2020
Q1 		$6K Buy
+12
New +$4.95K ﹤0.01% 736
2018
Q2 		– Sell
-32
Closed -$11K – 828
2018
Q1 		$11K Sell
32
-100
-76% -$34.8K ﹤0.01% 682
2017
Q4 		$50K Buy
132
+32
+32% +$13K ﹤0.01% 447
2017
Q3 		$45K Hold
100
– – ﹤0.01% 461
2017
Q2 		$49K Hold
100
– – ﹤0.01% 459
2017
Q1 		$39K Hold
100
– – ﹤0.01% 485
2016
Q4 		$37K Hold
100
– – ﹤0.01% 483
2016
Q3 		$40K Hold
100
– – ﹤0.01% 466
2016
Q2 		$35K Hold
100
– – ﹤0.01% 496
2016
Q1 		$36K Buy
+100
New +$41.2K ﹤0.01% 488

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sandy Spring Bank's REGN Position: Q1 2025 in Review

Sandy Spring Bank reduced its Regeneron Pharmaceuticals (REGN) stake by 21% in Q1 2025, selling an estimated $8.94K and leaving 50 shares worth $31.7K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Sandy Spring Bank first reported a position in REGN in Q1 2016 and has held it in 30 quarters since. The position peaked at $197K in Q3 2023. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Sandy Spring Bank held 50 shares of Regeneron Pharmaceuticals worth $31.7K as of Q1 2025.
  • Sandy Spring Bank sold 13 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $8.94K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #657 holding.
  • Sandy Spring Bank first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 30 quarters since.
  • Sandy Spring Bank's Regeneron Pharmaceuticals position peaked at $197K in Q3 2023.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.